The NSAID and CVD Balancing Act
The NSAID and CVD Balancing Act
Daniel Solomon, MD, MPH, is an Associate Professor of Medicine at Harvard Medical School and Chief of the Section of Clinical Sciences in Rheumatology at Brigham and Women's Hospital, where he is coappointed in the Division of Pharmacoepidemiology and Pharmacoeconomics. The focus of his research is health services research, quality of care, and pharmacoepidemiology as it pertains to rheumatic diseases and osteoporosis. Specific topics of interest include: indicators of quality prescribing, patterns of medication use for osteoporosis, quality improvement in osteoporosis care, and cardiovascular disease in patients with rheumatoid arthritis. Dr. Solomon is the Past Chair of the Quality of Care Committee of the American College of Rheumatology. He serves as an unpaid member of the Executive Committee on the PRECISION trial assessing the cardiovascular safety of celecoxib vs nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) and as an unpaid member of the Data and Safety Monitoring Board for trials testing a nerve growth factor inhibitor, tanezumab.
A Best Evidence Interview With Daniel Solomon, MD
About the Interviewee
Daniel Solomon, MD, MPH, is an Associate Professor of Medicine at Harvard Medical School and Chief of the Section of Clinical Sciences in Rheumatology at Brigham and Women's Hospital, where he is coappointed in the Division of Pharmacoepidemiology and Pharmacoeconomics. The focus of his research is health services research, quality of care, and pharmacoepidemiology as it pertains to rheumatic diseases and osteoporosis. Specific topics of interest include: indicators of quality prescribing, patterns of medication use for osteoporosis, quality improvement in osteoporosis care, and cardiovascular disease in patients with rheumatoid arthritis. Dr. Solomon is the Past Chair of the Quality of Care Committee of the American College of Rheumatology. He serves as an unpaid member of the Executive Committee on the PRECISION trial assessing the cardiovascular safety of celecoxib vs nonselective nonsteroidal anti-inflammatory drugs (NSAIDs) and as an unpaid member of the Data and Safety Monitoring Board for trials testing a nerve growth factor inhibitor, tanezumab.
